On 24 December 2016, after the last two multi-center clinical study protocol discussions, the third multi-center clinical study protocol initiation meeting of sultamicillin for suspension was officially held in Shenzhen.Authoritative experts from all over the country were invited: Dean Shen Kunling, Beijing Children's Hospital affiliated to Capital Medical University; Yang Yonghong, President of Asian Society of Pediatric Infections; Chen Qiang, President of Jiangxi Children's Hospital; Professor Zheng Bo, Peking University First Hospital; Professor Shiluwen, Peking University School of Pharmacy; Professor Lu Min, Shanghai Children's Hospital.Prof. Wu Beirong, Shanghai Children's Hospital, Bao Yanmin, Shenzhen Children's Hospital, Zhao Chengsong, Beijing Children's Hospital, Zeng Xiantao, Central South Hospital, Wuhan University, Han Zhiying, Shanxi Children's Hospital, Zhang Junyan, Shanxi Children's Hospital, Zhang Chuan, West China Second Hospital, Shengjing Hospital Li Xiaowen,Yin Qingfeng, General Manager, Jiangsu Famisheng Medical Technology Co., Ltd. The meeting provided clear instructions on the finalization of the multicenter clinical protocol.

The meeting was chaired by President Shen Kunling, President Yang Yonghong and Professor Shi Luwen. The theme of the meeting and sultamicillin were introduced in detail.

Then, Wu Guangmei, chairman of Shenzhen Beimei Pharmaceutical Co., Ltd. made a brief introduction to the company.

Next, the plan was introduced in detail by Prof. Chen Zun of Jiangsu Famisen Medical Technology Co., Ltd.

President Shen Kunling summarized the plan, put forward questions and guidance, and actively discussed with the experts present to ensure the feasibility of the implementation of the final plan, and so on.

This meeting has come to an end with the lively discussion of experts, and also foreshadows that the multi-center clinical study of sultamicillin for suspension will be officially implemented in major hospitals in 2017. Let us look forward to the satisfactory results of sultamicillin for suspension in clinical practice.